Federated Hermes
AMLX icon

Federated Hermes’s Amylyx Pharmaceuticals AMLX Stock Holding History

Federated Hermes’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.3M Buy
462,205
+98,659
+27% +$1.53M 0.01% 740
2026
Q1 		$5.05M Sell
363,546
-93,866
-21% -$1.32M 0.01% 801
2025
Q4 		$5.53M Buy
457,412
+245,033
+115% +$3.33M 0.01% 764
2025
Q3 		$2.89M Buy
212,379
+8,449
+4% +$79.5K 0.01% 850
2025
Q2 		$1.31M Buy
203,930
+1,145
+0.6% +$5.57K ﹤0.01% 1053
2025
Q1 		$718K Buy
202,785
+469
+0.2% +$1.67K ﹤0.01% 1199
2024
Q4 		$765K Buy
202,316
+16,030
+9% +$75.4K ﹤0.01% 1193
2024
Q3 		$604K Buy
186,286
+7,512
+4% +$16.9K ﹤0.01% 1288
2024
Q2 		$340K Buy
178,774
+2,791
+2% +$5.41K ﹤0.01% 1394
2024
Q1 		$500K Buy
175,983
+73,483
+72% +$961K ﹤0.01% 1321
2023
Q4 		$1.51M Sell
102,500
-221,760
-68% -$3.4M ﹤0.01% 1022
2023
Q3 		$5.94M Sell
324,260
-1,204,740
-79% -$25.5M 0.02% 654
2023
Q2 		$33M Sell
1,529,000
-317,117
-17% -$8.56M 0.08% 279
2023
Q1 		$54.2M Buy
1,846,117
+231,272
+14% +$8.03M 0.14% 180
2022
Q4 		$59.7M Buy
1,614,845
+285,845
+22% +$10.1M 0.17% 155
2022
Q3 		$37.4M Buy
+1,329,000
New +$33.2M 0.11% 228

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Federated Hermes's AMLX Position: Q2 2026 in Review

Federated Hermes increased its Amylyx Pharmaceuticals (AMLX) stake by 27% in Q2 2026, buying an estimated $1.53M and bringing the position to 462,205 shares worth $8.3M. The position accounts for 0.01% of the portfolio, ranked #740.

Federated Hermes first reported a position in AMLX in Q3 2022 and has held it in 16 quarters since. The position peaked at $59.7M in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Federated Hermes held 462,205 shares of Amylyx Pharmaceuticals worth $8.3M as of Q2 2026.
  • Federated Hermes bought 98,659 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
  • Amylyx Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #740 holding.
  • Federated Hermes first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Federated Hermes's Amylyx Pharmaceuticals position peaked at $59.7M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.